Artificial Cell Technologies, Inc. Company Profile

12:48 EDT 20th September 2018 | BioPortfolio

Artificial Cell Technologies, Inc. is an early-stage biomedical nanotechnology company founded in 2002 to commercialize applications of a new proprietary technology platform involving designed polypeptides. Our long term vision is to commercialize biotechnology applications for successively more sophisticated versions of an artificial bionanomachine: the artificial cell. ACT was founded to achieve this artificial cell vision by commercializing biomedical applications of our proprietary polypeptide nanostructure technology platform, starting with one of the simplest of human cells, the red blood cell. ACT’s technology platform includes proprietary methods for manufacturing custom-designed polypeptide films and microcapsules with controlled, tunable biological, chemical, and physical properties.


5 Science Park Suite 13
New Haven
United States of America


Phone: 203-772-3430
Fax: 203-567-8073

News Articles [2096 Associated News Articles listed on BioPortfolio]

New artificial cell successfully minimised to target and kill specific bacteria.

An artificial cell is a bioengineered particle which mimics a naturally occuring biological cell. The hypothesis is that the synthetic biologic biomimics some of the properties of cells, such as surfa...

#news #biotech A photosynthetic engine for artificial cells

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: A photosynthetic engine for artificial cells .In the quest to build an artifi...

Artificial molecules that mimic DNA

(CNRS) French researchers have developed an artificial sequence mimicking the surface features of DNA for the first time. This artificial molecule is able to inhibit the activity of several DNA-bindin...

Optical Tweezing Lasers Sculpt Artificial Cell Membranes

Made-to-order cells may soon transition from the realm of science fiction to the reality of science and medicine, as researchers from Imperial College London and Loughborough University have demonstra...

China and Israel Are Ready to Battle: Who Leads the Medical Imaging Artificial Intelligence Market?

In October 2017, China’s State Council laid out a plan to develop a domestic artificial intelligence (AI) industry worth $150 billion by 2030, with the aim of becoming a global leader in AI technolo...

Stem Cell Sciences: Stem Cell Technologies: The End of the Beginning

In this exclusive interview, Fintan Walton talks to Peter Mountford, formerly CEO of Stem Cell Sciences, about the current state of stem cell technologies and their potential healthcare and research a...

Artificial Intelligence Takes Scientists Inside Living Human Cells

(NPR) – A new application of artificial intelligence could help researchers solve medical mysteries ranging from cancer to Alzheimer’s. It’s a 3D model of a living human cell that le...

Living Cell Technologies: New Technologies and Clinical Trials

In this episode of PharmaTelevision News Review, Fintan Walton talks with Dr Paul Tan, CEO of Living Cell Technologies. Filmed at AusBiotech 2009, they discuss: • The company’s origins and aims ...

PubMed Articles [3570 Associated PubMed Articles listed on BioPortfolio]

The impact of single-cell RNA sequencing on understanding the functional organization of the immune system.

Application of single-cell genomics technologies has revolutionized our approach to study the immune system. Unravelling the functional diversity of immune cells and their coordinated response is key ...

An artificial intelligent single cell is part of the cell dream world.

Macular Vessel Density and Ganglion Cell/Inner Plexiform Layer Thickness and Their Combinational Index Using Artificial Intelligence.

To evaluate the relationship between macular vessel density and ganglion cell to inner plexiform layer thickness (GCIPLT) and to compare their diagnostic performance. We attempted to develop a new com...

Unleashing the Therapeutic Potential of CAR-T Cell Therapy Using Gene-Editing Technologies.

Chimeric antigen receptor (CAR) T-cell therapy, an emerging immunotherapy, has demonstrated promising clinical results in hematological malignancies including B-cell malignancies. However, accessibili...

Journal of Artificial Organs 2017: the year in review : Journal of Artificial Organs Editorial Committee.

Clinical Trials [7056 Associated Clinical Trials listed on BioPortfolio]

Safety and Efficacy of an Artificial Tear for the Treatment of Dry Eye

The efficacy, safety and acceptability of a new artificial tear in subjects with dry eye will be compared to a currently-available artificial tear

Artificial Shrinkage for Human Blastocyst Prior Vitrification

Investigators aim to investigate the effect of elimination of blastocoelic fluid by creating a large hole in the zona pellucida at the cellular junction of the trophectoderm cells located ...

A Comparison of Orally Pilocarpine and Artificial Saliva in Xerostomy Treatment

The purpose of this study is to assess and compare the safetyness and efficacy of pilocarpine drops versus artificial saliva as symptomatic treatment for dry mouth and dry eyes caused by...

Establishment of Comprehensive Genetic Analysis From a Single Cell

Preimplantation genetic diagnosis (PGD) is the integration of both assisted reproductive technologies and molecular genetic technologies and was shown to improve implantation rate and redu...

The Visual Effect of an Investigational Artificial Tear in the Tear Layer.

The purpose of this study is to investigate how the addition of a new artificial tear product when applied to the tear layer affects contrast sensitivity and optical aberrations over time....

Companies [2353 Associated Companies listed on BioPortfolio]

Artificial Cell Technologies, Inc.

Artificial Cell Technologies, Inc. is an early-stage biomedical nanotechnology company founded in 2002 to commercialize applications of a new proprietary technology platform involving designed polypep...

Kurzweil Technologies, Inc.

Kurzweil Technologies, Inc. (KTI) is a research and development company developing and marketing technologies in pattern recognition, artificial intelligence, evolutionary algorithms, signal processin...

ReNeuron Group plc

ReNeuron Group plc is a leading player in the stem cell field, using human somatic stem cells to develop leading edge therapies for neurodegenerative and other diseases. We are also leveraging our ste...

SynCardia Systems, Inc.

SynCardia Systems, Inc. is the Tucson-based manufacturer of the world’s only FDA, Health Canada and CE approved Total Artificial Heart: the SynCardia temporary Total Artifici...


MyoPowers Medical Technologies SA was founded by Dr Piergiorgio Tozzi, MD, of the University Hospital of Lausanne (CHUV), Switzerland and Professor Daniel Hayoz of the Cantonal Ho...

More Information about "Artificial Cell Technologies, Inc." on BioPortfolio

We have published hundreds of Artificial Cell Technologies, Inc. news stories on BioPortfolio along with dozens of Artificial Cell Technologies, Inc. Clinical Trials and PubMed Articles about Artificial Cell Technologies, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Artificial Cell Technologies, Inc. Companies in our database. You can also find out about relevant Artificial Cell Technologies, Inc. Drugs and Medications on this site too.

Quick Search


Relevant Topic

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Corporate Database Quicklinks

Searches Linking to this Company Record